CDSCO Shifts To Risk-Based Drug Approvals To Ease Compliance

India's CDSCO is reviewing its drug approval pathways with the explicit aim of reducing regulatory intervention where risk profiles permit, a directional shift that carries direct implications for manufacturers operating under or seeking entry into one of the world's largest generics markets. Dr. Ranga Chandrashekhar, Joint Drug Controller at CDSCO, confirmed the regulator's intent to identify intervention points that can be scaled back without compromising established safeguards.

The framing is consistent with risk-based quality management principles embedded in ICH Q10 and broadly aligned with how mature regulators such as the US FDA and EMA have structured tiered oversight. For QA directors and regulatory affairs leads managing India-facing dossiers, the signal is that submission strategies and compliance architectures built around uniform, high-intervention assumptions may warrant reassessment as the framework evolves.

Chandrashekhar's remarks did not specify which approval categories or product classes are under review, nor did they indicate a timeline for formal guidance. That absence of detail is operationally significant: manufacturers cannot yet recalibrate validation packages or 21 CFR Part 211-equivalent local compliance documentation in anticipation of reduced scrutiny, because the scope of reduction remains undefined. Plant heads preparing for CDSCO inspections should treat current GMP expectations as unchanged until draft guidance materialises.

The broader context is India's sustained effort to align its regulatory posture with international standards, a trajectory that has included Schedule M revisions and increased engagement with the Pharmaceutical Inspection Co-operation Scheme. A risk-based model, if implemented with the granularity seen in ICH Q9(R1), would require manufacturers to demonstrate robust risk identification and control strategies, potentially shifting the compliance burden rather than simply reducing it.

Formal guidance detailing which product classes or approval stages fall within the reduced-intervention scope will be the measurable checkpoint against which this policy direction can be assessed.

Source: Media4Growth via Indian Pharma Post, 8 September 2026.